Literature DB >> 12200604

Antibody responsiveness to the enteropathogenic Escherichia coli bundle-forming pilus subunit A in lactating mothers and asymptomatic children.

Regina Célia de Souza Campos Fernandes1, Victor Martin Quintana Flores, Zila Sousa de Macedo, Enrique Medina-Acosta.   

Abstract

UNLABELLED: The objective of this study was to examine the antibody responsiveness to the bundle-forming pilus subunit A of enteropathogenic Escherichia coli in human colostrum (n = 36) and serum (n = 90) of paediatric ambulatory patients, 3-24 months of age. Affinity purified recombinant bundle-forming pilus subunit A was used in immunoblot analysis to detect antigen-specific serum immunoglobulins G and A, and colostrum immunoglobulin A. Circulating immunoglobulin G antibody activity to the bundle-forming pilus subunit A was readily detected in all children. The frequency of immunoglobulin A antibody activity to the bundle-forming pilus subunit A in serum was 83.3%. Immunoglobulin A antibody activity to the bundle-forming pilus subunit A was detected in 75% of colostrum samples. The high frequency of immunoglobulin A antibody activity to the bundle-forming pilus subunit A observed in serum reveals a predominance of typical enteropathogenic Escherichia coli priming/infection in the study population.
CONCLUSION: these findings demonstrate that the bundle-forming pilus subunit A is immunogenic, for both immunoglobulins G and A, in both pregnant/lactating women and asymptomatic children.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200604     DOI: 10.1007/s00431-002-0995-8

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  1 in total

1.  Colostrum from healthy Brazilian women inhibits adhesion and contains IgA antibodies reactive with Shiga toxin-producing Escherichia coli.

Authors:  Patricia Palmeira; Solange Barros Carbonare; José Araujo Amaral; Milene Tino-De-Franco; Magda Maria Sales Carneiro-Sampaio
Journal:  Eur J Pediatr       Date:  2004-11-10       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.